Organization
Charité Universitätsmedizin Berlin, Berlin, Germany
4 abstracts
Abstract
AN OPEN-LABEL STUDY TO EVALUATE BIOMARKERS AND SAFETY IN SYSTEMIC SCLEROSIS (SSC) PATIENTS TREATED WITH PAQUINIMOD (ABR-215757) Org: Skåne University Hospital, Lund, Sweden, University of Erlangen-Nuremberg, Erlangen, Germany, Charité Universitätsmedizin Berlin, Berlin, Germany, Active Biotech AB, Lund, Sweden, University Hospital Zurich, Zurich, Switzerland,
Abstract
Adalimumab serum concentration fails to predict achievement of sustained remission or absence of flare for patients with non-radiographic axial spondyloarthritis in the ability-3 studyOrg: AbbVie Inc., North Chicago, IL, Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, Swedish Medical Center and University of Washington, Seattle, USA, Charité Universitätsmedizin Berlin, Berlin, Germany, Amsterdam Rheumatology and Clinical Immunology Center, Amsterdam, Netherlands,
Abstract
ARE THE MODIFIED NEW YORK AND ASAS AXIAL SPONDYLOARTHRITIS CRITERIA INTERCHANGEABLE IN THE CLASSIFICATION OF SPONDYLOARTHRITIS PATIENTS WITH RADIOGRAPHIC SACROILIITIS: COMPARISON IN 8 COHORTS?Org: Charité Universitätsmedizin Berlin, Berlin, Germany, German Rheumatism Research Centre, Berlin, Germany, Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany,
Abstract
Baricitinib in systemic lupus erythematosus (SLE): results from a phase 2, randomised, double-blind, placebo-controlled studyOrg: Cedars-Sinai Medical Center/UCLA, Los Angeles, Hofstra Northwell School of Medicine, New York, USA, Univ of Occupational and Environmental Health, Kitakyushu, Japan, Univ of California at San Diego School of Medicine, La Jolla, USA, Univ of Pisa, Pisa, Italy,